View Clinical trials for Avacopan Get Avacopan Patent Info for Free

CCX168 (avacopan) is a small molecule that targets the chemoattractant receptor known as C5aR, and is being developed for inflammatory and autoimmune diseases. CCX168 blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR.

Inn NameAvacopan
Usan NameAvacopan
Lab CodesCCX-168
Chemical Name(2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
Chemical StructureAvacopan.png
Molecular FormulaC33H35F4N3O2
Cas Registry Number1346623-17-3
Orphan Drug StatusYes
Orphan IndicationAnti-neutrophil cytoplasmic antibody-associated vasculitis, Haemolytic uraemic syndrome
New Molecular EntityYes
DeveloperMario Negri Institute for Pharmacological Research
Mechanism Of ActionComplement C5a receptor antagonist
Who Atc CodesL04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products)
Ephmra CodesL4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products)
IndicationImmunoglobulin A Nephropathy, Atypical Hemolytic Uremic Syndrome, Vasculitis, ANCA-associated Vasculitis

Free counters!